BrainsWay Ltd.
NASDAQ:BWAYMedical - Devices
+$0.05 today
- Market cap
- $352.22M
- Beta
- 0.15
- P/E (TTM)
- 61.7
- EPS (TTM)
- $0.23
Volume 0.15M
Average 0.15M
BWAY EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
BrainsWay Ltd.NASDAQ: BWAY
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA grows, but more slowly than its trailing trend
Q1 FY2026 EBITDA of $3.19M rose 42.3% year over year, behind the +90.6% change in trailing-twelve-month EBITDA. Sequentially, it fell 3.9% from the prior quarter.
Context
- EBITDA amounted to 21.9% of revenue in FY2025, up 8.9 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of $11.17M (-2.5%) for the fiscal year ending Dec 2026, a slowdown from the +113.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $3.19M-3.9% QoQ
- Last fiscal yearDec 2025
- $11.46M+113.9% YoY
- LTMMar 2026
- $12.57M+90.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +42.3% | +4.2% | -38.1 pp |
| 1 year | +113.9% | -2.5% | -116.4 pp |
| 3-year CAGR | — | +17.6% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 11.46M USD
- Year-over-year change
- +113.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.46M | +113.9% |
| FY2024 | 2024-12-31 | 5.36M | +309.2% |
| FY2023 | 2023-12-31 | (2.56M) | +77.6% |
| FY2022 | 2022-12-31 | (11.45M) | -145.1% |
| FY2021 | 2021-12-31 | (4.67M) | — |
EBITDA vs competitors
How BWAY compares with its peers on the latest reported figures
- BWAY's LTM Mar 2026 EBITDA of $12.57M is the highest of the 4 companies compared; the peer median is -$25.7M.
- Its year-over-year change of +90.6% is the highest of 4, against a peer median of +3.2%.
- EBITDA amounts to 22.4% of revenue for BWAY, versus a peer median of 17.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.57M | +90.6% | — | 22.4% | |
| LTM Mar 2026 | -$13.84M | +3.2% | — | 13.9% | |
| LTM Mar 2026 | -$25.7M | +34.0% | — | 17.0% | |
| LTM Mar 2026 | -$135.55M | -1012.4% | — | 1413.6% | |
MOBIMobia Medical, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding BWAY) | -$25.7M | +3.2% | — | 17.0% | |
Competitors are the stored peer set for BWAY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 29.66M | 27.18M | 31.79M | 41.02M | 52.23M |
| Cost of Revenue | 6.6M | 7.13M | 8.31M | 10.44M | 12.84M |
| Gross Profit | 23.06M | 20.05M | 23.48M | 30.58M | 39.39M |
| Gross Margin | 77.7% | 73.8% | 73.9% | 74.6% | 75.4% |
| Research & Development | 6.39M | 7.68M | 6.67M | 7.19M | 9.6M |
| Selling, General & Admin | 21.66M | 25.05M | 21.64M | 22M | 25.46M |
| Operating Expenses | 28.06M | 32.73M | 28.44M | 29.19M | 35.06M |
| Depreciation & Amortization | 1.69M | 1.53M | 1.34M | 1.77M | 1.54M |
| EBITDA | (4.67M) | (11.45M) | (2.56M) | 5.36M | 11.46M |
| EBITDA Margin | -15.8% | -42.1% | -8.1% | 13.1% | 21.9% |
| Operating Income | (5M) | (12.68M) | (4.96M) | 1.39M | 4.32M |
| Operating Margin | -16.9% | -46.7% | -15.6% | 3.4% | 8.3% |
| Interest Income | 225K | 1.11M | 2.17M | 2.48M | 5.64M |
| Interest Expense | 141K | 68K | 298K | 1.36M | 2.23M |
| Other Income / Expenses | (1.42M) | (351K) | 1.01M | 2.07M | 3.39M |
| Income Before Tax | (6.42M) | (13.03M) | (3.95M) | 3.46M | 7.71M |
| Pre-Tax Margin | -21.6% | -48.0% | -12.4% | 8.4% | 14.8% |
| Income Tax Expense | 43K | 315K | 251K | 538K | 77K |
| Net Income | (6.46M) | (13.35M) | (4.2M) | 2.92M | 7.63M |
| Net Margin | -21.8% | -49.1% | -13.2% | 7.1% | 14.6% |
| EPS (Basic) | (0.21) | (0.43) | (0.13) | 0.09 | 0.40 |
| EPS (Diluted) | (0.21) | (0.43) | (0.13) | 0.09 | 0.36 |
| Weighted Avg Shares | 31.15M | 32.98M | 33.16M | 33.97M | 19.08M |
| Weighted Avg Shares (Diluted) | 31.15M | 32.98M | 33.16M | 34.77M | 21.21M |
BrainsWay Ltd.
NASDAQ:BWAY
Intrinsic Alpha fair value
Locked
Current Price
$8.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.